Lehrstuhl für Geburtshilfe und Frauenheilkunde

Germline variants of homology-directed repair or mismatch repair genes in cervical cancer () Kokemüller L, Ramachandran D, Schürmann P, Geffers R, Jentschke M, Böhmer G, Strauß HG, et al. Journal article HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevance () Branz A, Matek C, Lange F, Bahlinger V, Klümper N, Hölzel M, Strissel P, et al. Journal article Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer (2025) Hoppe R, Winter S, Lo WY, Michailidou K, Bolla MK, Keeman R, Wang Q, et al. Journal article Effect of delayed isolation of peripheral blood mononuclear cells on cell viability and functionality (2025) Lehle S, Völkl S, Seitz K, Goossens C, Emons J, Rübner M, Uhrig S, et al. Journal article Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis (2025) Fu Z, Borho L, Taylor SE, Kelemen LE, DeFazio A, Webb PM, Köbel M, et al. Journal article Update Gynecologic Malignancies 2025 – Expert Opinion on Systemic Therapy for Early and Advanced Gynecological Cancers Update gynäkologische Tumoren 2025 – Expertenmeinung zur systemischen Therapie für die Behandlung von frühen und fortgeschrittenen gynäkologischen Tumoren (2025) Emons J, Gocke J, Schulmeyer C, Stübs F, Krückel A, Amann N, Beckmann M, et al. Journal article Treatment of Patients with Early Breast Cancer 19th St. Gallen International Breast Cancer Consensus Discussed against the Background of German Treatment Recommendations Behandlung von Patientinnen mit fruhem Mammakarzinom 19. Internationaler St..Gallen.Konsens vor dem Hintergrund deutscher Therapieempfehlungen diskutiert (2025) Untch M, Banys-Paluchowski M, Brucker SY, Denkert C, Fasching P, Haidinger R, Harbeck N, et al. Journal article, Review article Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk (2025) Müller V, Hörner M, Thill M, Banys-Paluchowski M, Schmatloch S, Fasching P, Harbeck N, et al. Journal article Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer (2025) O'Shaughnessy J, Tolaney SM, Yardley DA, Hart L, Razavi P, Fasching P, Janni W, et al. Journal article Impact of risk and lifestyle factors on therapy goals in the treatment of breast cancer and gynecological cancer patients with integrative medicine (2025) Seitz K, Theuser AK, Antoniadis S, Beckmann M, Beierlein M, Brückner L, Au K, Hack C Journal article